Filtered By:
Condition: Arrhythmia
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 249 results found since Jan 2013.

Current and emerging pharmacotherapy for ischemic stroke prevention in patients with atrial fibrillation.
Authors: Székely O, Miyazawa K, Lip GYH Abstract INTRODUCTION: Atrial fibrillation (AF) is associated with high morbidity and mortality rates due to thromboembolic complications, and anticoagulation is central to the management of this common arrhythmia to prevent acute thromboembolic events. The traditional anticoagulants: heparin, fondaparinux, and vitamin K antagonists (VKA, e.g. warfarin, acenocoumarol or phenprocoumin) have long served as pharmacotherapy for ischemic stroke prophylaxis. Areas covered: In this review article, the authors provide an overview on current and emerging pharmacotherapy for ischemic ...
Source: Expert Opinion on Pharmacotherapy - October 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

The change of paradigm in stroke prevention in atrial fibrillation. Challenges and emerging opportunities for the family physician.
Abstract Atrial fibrillation (AF), is the most prevalent sustained arrhythmia in general population, affecting up to 10% in patients of advanced age. AF doubles overall mortality and increases up to 5-6 times the risk of stroke, which have the characteristic of being particularly harmfull. The basis of treatment on AF are the rhythm or rate control and the prevention of thromboembolism. For the latter purpose the treatments that have been most effective are oral acticoagulants. For decades and until just a few years ago, the only oral drugs available for this purpose have been the anti-vitamin K, mainly represente...
Source: Atencion Primaria - April 1, 2013 Category: Primary Care Authors: Castillo Rodríguez JC, Lozano IF Tags: Aten Primaria Source Type: research

A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals.Trial registration:Clinical-Trials.gov: NCT03367325. Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral an...
Source: Medicine - January 1, 2018 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Stroke prevention in the elderly: effectiveness and safety of edoxaban in elderly patients according to the results of the ENGAGE AF study.
Abstract Atrial fibrillation is the most common clinically relevant arrhythmia frequently causing systemic thromboembolic events. Traditionally vitamin K antagonists had been used for decades to prevent these events. The emerging of the new direct anticoagulants has revolutionized this treatment and a gradual growth and extensive spread of usage is expected. The latest one approved in Hungary, edoxaban, is a factor Xa inhibitor. Once-daily administration and favourable safety profile are major benefits of this drug. In a large clinical study with a high number of patients it proved to be at least as effective as w...
Source: Orvosi Hetilap - May 1, 2018 Category: General Medicine Authors: Márk L Tags: Orv Hetil Source Type: research

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants.
Abstract Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago, vitamin K antagonists (VKAs) and low molecular weight heparin represented the only option to prevent thromboembolisms, though with risks. Novel oral anticoagulants (NOACs) have radically changed the management of AF patients, improving both life expectancy and life quality. This review aims to summarize the mo...
Source: Medicina (Kaunas) - September 19, 2019 Category: Universities & Medical Training Authors: Caturano A, Galiero R, Pafundi PC Tags: Medicina (Kaunas) Source Type: research

Left atrial appendage closure for stroke prevention in nonvalvular atrial fibrillation: A current overview
J Cardiol. 2022 Nov 15:S0914-5087(22)00277-5. doi: 10.1016/j.jjcc.2022.11.006. Online ahead of print.ABSTRACTAtrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and its prevalence increases with age. AF causes palpitations, heart failure, and cardiogenic embolism. Of them, the most critical and fatal complication is a cardio-embolic event. Oral anticoagulation plays a central role in reducing stroke risk in AF patients. Recently, when oral anticoagulation is considered in patients with non-valvular AF who are eligible for direct oral coagulations, they are preferred to vitamin K antagoni...
Source: Journal of Cardiology - November 18, 2022 Category: Cardiology Authors: Hiroshi Ueno Teruhiko Imamura Shuhei Tanaka Nobuyuki Fukuda Koichiro Kinugawa Source Type: research

End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience Original Articles
Conclusions— The excess of events at EOS was likely because of a period of inadequate anticoagulation in rivaroxaban participants switched to vitamin K antagonist therapy. If transition from rivaroxaban to vitamin K antagonist is needed, timely monitoring and careful dosing should be used to ensure consistent and adequate anticoagulation.
Source: Circulation: Cardiovascular Quality and Outcomes - July 16, 2013 Category: Cardiology Authors: Mahaffey, K. W., Hellkamp, A. S., Patel, M. R., Hannan, K. L., Schwabe, K., Nessel, C. C., Berkowitz, S. D., Halperin, J. L., Hankey, G. J., Becker, R. C., Piccini, J. P., Breithardt, G., Hacke, W., Singer, D. E., Califf, R. M., Fox, K. A. A. Tags: Platelet function inhibitors, Arrhythmias, clinical electrophysiology, drugs, Embolic stroke, Anticoagulants Original Articles Source Type: research

In people with atrial fibrillation receiving antithrombotics, short-term non-steroidal anti-inflammatory drug exposure increases risk of serious bleeding
Commentary on: Lamberts M, Lip GYH, Hansen ML, et al. Relation of non-steroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy Ann Intern Med 2014;161:690–8. Implications for practice and research Short courses of non-steroidal anti-inflammatory drugs (NSAIDs) should be used with caution in patients with atrial fibrillation (AF) already taking antithrombotic therapy for stroke prevention since there is an increased risk of serious bleeding and clot formation. Research needs to be carried out on whether combined NSAID and non-v...
Source: Evidence-Based Nursing - December 15, 2015 Category: Nursing Authors: Myat, A. Tags: GI bleeding, Adult nursing, Drugs: cardiovascular system, Pain (neurology), Stroke, Ischaemic heart disease, Pain (palliative care), Pain (anaesthesia), Drugs: musculoskeletal and joint diseases, Arrhythmias Source Type: research

The anticoagulation choices of internal medicine residents for stroke prevention in non-valvular atrial fibrillation
Conclusions Canadian internal medicine residents favoured warfarin over NOACs for patients with NVAF, which is in discordance with the evidence-based CCS guidelines. This finding persisted throughout the 3 years of core internal medicine training.
Source: Postgraduate Medical Journal - May 25, 2017 Category: General Medicine Authors: Moulson, N., McIntyre, W. F., Oqab, Z., Yazdan-Ashoori, P., Quinn, K. L., van Oosten, E., Hopman, W. M., Baranchuk, A. Tags: Drugs: cardiovascular system, Stroke, Arrhythmias Original article Source Type: research

Stroke risk assessment in atrial fibrillation: Beyond atrial rhythm
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, and is responsible for at least 20% of all strokes. Moreover, strokes associated to AF are largely avoidable, as the use of anti-vitamin K drugs can prevent>65% of all strokes, and direct oral anticoagulants con reduce the rate of stroke by a further 19% [1].
Source: International Journal of Cardiology - May 22, 2019 Category: Cardiology Authors: Giovanni Luca Botto, Francesco Maria Brasca Tags: Editorial Source Type: research

Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation
Expert Opin Investig Drugs. 2021 Mar 8. doi: 10.1080/13543784.2021.1897786. Online ahead of print.ABSTRACTINTRODUCTION: Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.AREAS COVERED: This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms...
Source: Expert Opinion on Investigational Drugs - March 8, 2021 Category: Drugs & Pharmacology Authors: Robert Bentley Lewis J Hardy Laura J Scott Parveen Sharma Helen Philippou Gregory Y H Lip Source Type: research